COVID-19 Boosts Sanofi's Ageing Lovenox Franchise, But Holds Back Travel Vaccine Sales
Vaccines Near Late-Stage Studies
The COVID-19 pandemic led to a marked increase in sales of Sanofi’s LMW heparin, Lovenox, in the first quarter of 2021. The big pharma is also nearing late-stage clinical studies with two COVID-19 vaccine candidates.
You may also be interested in...
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.